NCT06733298已完成1 期
Open-Label, Non-Randomized Study Investigating the Excretion Balance, Pharmacokinetics, and Metabolism of a Single Oral Dose of [14C]-Labeled RO7269162 in Healthy Male Participants
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Concentration of [14C] in whole blood
研究概览
简要总结
This study will investigate how RO7269162 labeled with a carbon tracer ([14C]) is absorbed, metabolized, and eliminated by the body after a single dose in healthy male volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 64 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male participants aged 35 to 64 years of age (inclusive), at screening
- •Body weight ≥ 50 kg and body mass index within the range 18 to 30 kg/m2 (inclusive), at screening
- •Male participants who, for 3 months after dosing of [14C]-RO7269162, agree to: remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol with a partner that is a woman of childbearing potential; remain abstinent or use contraception with a pregnant female partner; refrain from donating sperm
排除标准
- •History or evidence of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological, or allergic disease, metabolic disorder, cancer, or cirrhosis
- •Any disease or condition that could interfere with the conduct of the study or pose an unacceptable risk to the participant
- •History or evidence of any medical condition that could potentially alter the absorption, metabolism, or elimination of drugs
- •Surgical history of the gastrointestinal (GI) tract affecting gastric motility or altering the GI tract (with the exception of uncomplicated appendectomy and hernia repair)
- •History of malignancy
- •Use of any prescription drugs, herbal supplements, and/or over-the-counter medication (OTC), dietary supplements (vitamins included) within 2 weeks before Day
- •Use of any prohibited food before study start and during the study as defined by the protocol
- •Likely to need medication during the study period except for those defined by the protocol
- •Are currently enrolled in, have participated in, or plan to participate in any other clinical study involving an investigational medicinal product or medical device study from within the 30 days directly preceding screening or within 5 times the elimination half-life, if known (whichever is longer), until completion of the follow-up visit
- •Evidence of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- •Donation of blood or blood products for transfusion over 100 mL or significant blood loss within 2 months prior to screening through study completion, clinic discharge or early termination, inclusive. Donation of blood or plasma is not allowed throughout the entire study. Receipt of blood products within 2 months prior to Day -1 is not allowed
- •Clinically significant history of hypersensitivity or allergic reactions
- •Regular work with ionizing radiation or radioactive material, or exposure to ionizing radiation within 1 year prior to study drug administration
研究组 & 干预措施
Arm 1
Experimental
Participants will receive one oral dose of [14C]-labeled RO7269162 on Day 1.
干预措施: [ 14C]-labeled RO7269162 (Drug)
结局指标
主要结局
Concentration of [14C] in whole blood
时间窗: Up to Day 22 or Day 37
[14C] recovery in feces
时间窗: Up to Day 22 or Day 37
[14C] recovery in urine
时间窗: Up to Day 22 or Day 37
Plasma concentration of [14C]
时间窗: Up to Day 22 or Day 37
Plasma concentration of RO7269162
时间窗: Up to Day 22 or Day 37
Amount of RO7269162 excreted in urine
时间窗: Up to Day 22 or Day 37
次要结局
- Amount of RO7269162 metabolites in plasma(Up to Day 22 or Day 37)
- Amount of RO7269162 metabolites in blood(Up to Day 22 or Day 37)
- Amount of RO7269162 metabolites excreted in urine(Up to Day 22 or Day 37)
- Amount of RO7269162 metabolites excreted in feces(Up to Day 22 or Day 37)
- Incidence and severity of adverse events(Up to Day 22 or Day 37)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.HealthyNCT01970020Janssen Research & Development, LLC6
已完成
1 期
Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male SubjectsAlzheimer DiseaseNCT00906191Wyeth is now a wholly owned subsidiary of Pfizer6
已完成
1 期
A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT00908908Eisai Inc.6
已完成
1 期
An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy SubjectsHealthy SubjectsNCT04241393Cerevel Therapeutics, LLC12
已完成
1 期
A Study of the ADME of [14C]RIST4721 in Healthy Male SubjectsHealthyADMENCT05023811Aristea Therapeutics, Inc.6